These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 14585225)

  • 1. New therapeutic strategies for soft tissue sarcomas.
    von Mehren M
    Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
    Kopp HG; Patel S; Brücher B; Hartmann JT
    Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
    Hartmann JT; Patel S
    Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
    Hartmann JT
    Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
    Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
    Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
    Patel SR
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1789-93. PubMed ID: 12457438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
    Mita MM; Gong J; Chawla SP
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic management strategies for metastatic soft tissue sarcoma.
    Movva S; Verschraegen C
    Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
    Ratan R; Patel SR
    Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of new chemotherapy agents in soft tissue sarcoma.
    von Mehren M
    J Natl Compr Canc Netw; 2005 Mar; 3(2):198-205. PubMed ID: 19817029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perspectives on the oncologist pharmacopoeia].
    Lansiaux A; Bailly C
    Bull Cancer; 2003 Jan; 90(1):25-30. PubMed ID: 12609801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin for the treatment of soft tissue sarcomas.
    De Sanctis R; Marrari A; Santoro A
    Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of systemic therapy in sarcoma.
    Constantinidou A; Pollack S; Loggers E; Rodler E; Jones RL
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):211-23. PubMed ID: 23406562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ET-743: the French experience.
    Brain EG
    Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
    Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A
    Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin therapy for sarcomas.
    Casali PG; Sanfilippo R; D'Incalci M
    Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
    Benavent M; de Miguel MJ; Garcia-Carbonero R
    Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
    Bay JO; Cabrespine A; Gilliot O; Bailly C; Vincent C; Mishellany F; Gimbergues P
    Bull Cancer; 2007; 94 Spec No Actualites():S122-6. PubMed ID: 17845981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.